Taipei and Singapore, 2024/07/29 – Protect Animal Health (PAH) and DotBio, two pioneering companies in the field of biopharmaceuticals, are thrilled to announce a strategic collaboration to develop innovative therapeutic antibody discovery platform technologies and a therapeutic antibody pipeline specifically tailored for dogs and cats. This partnership aims to address the unmet medical needs of pets, providing advanced treatments and improving the quality of life for companion animals worldwide.

With a shared commitment to advancing veterinary medicine, PAH and DotBio are combining their expertise to create a fully integrated therapeutic antibody discovery platform. This platform will leverage DotBio’s cutting-edge technologies and proprietary methodologies to identify and develop novel therapeutic antibodies targeting a range of diseases prevalent in canine and feline populations.

"At PAH, our mission has always been to enhance the health and well-being of pets. This collaboration with DotBio represents a significant step forward in achieving that goal," said Haolin Sung, CEO of PAH. "By combining our extensive knowledge in veterinary medicine with DotBio's expertise in antibody discovery and engineering, we are poised to make groundbreaking advancements in the treatment of diseases that affect our beloved pets."

DotBio's innovative approach to antibody discovery, which includes its proprietary modular humanized and stabilized domain antibody technology platform (the DotBodies), as well as its intracellular antibody technology platform, will be

instrumental in the development of these therapeutic solutions. This collaboration will enable the rapid identification and optimization of high-affinity antibodies, including multi-specific antibodies, ensuring the development of effective and safe treatments for

various conditions, including autoimmune diseases, cancers, and chronic inflammatory disorders.

"Pet therapies are three decades behind those available for humans. We are thrilled to partner with PAH to revolutionize the treatment options available for our furry friends," said Ignacio Asial, Founder and CEO of DotBio. "Together, we aim to address the pressing medical needs of dogs and cats, bringing to pets the state-of-the-art therapeutic solutions currently available only to humans, such as multi-specific antibodies and immuno-modulatory therapies."

About PAH

Protect Animal Health is a Taiwanese life science development company specializing in companion animal care, dedicated to making advanced therapies accessible for pets, driving the change for the outdated animal health landscape. Beyond oncology drugs, Protect Animal Health utilizes human drug development expertise to tackle unmet needs in all high-potential disease areas in pets, also acting as an incubator of valuable companion animal drug pipelines.

About DotBio

DotBio is a Singaporean biopharmaceutical company specializing in next-generation antibody therapies. DotBio has a proprietary humanized, stable Domain Therapeutic Antibody (“DotBody”) platform technology that simplifies the process of generating multi-specific therapies. DotBio currently possesses proprietary state-of-the-art DotBody libraries and phage display libraries, a directed evolution and stabilization Colony Filtration (“CoFi”) technology, a Targeted Engineered Viral-Like Particle (“teVLP”) technology for intracellular antibody delivery, and numerous target-specific Dot antibody modules, as well as numerous pre-clinical assets in the immuno-oncology field.

PAH Contact Information Sean Liour

Chief Project Officer

Tel No.: +886 2727 6289

Email: sean.liour@protectvac.com https://www.protectvac.com/

DotBio Contact Information Kelly Hew

Chief Operation Officer Tel No.: +65 6906 0743

Email: kelly.hew@dotbiopharma.com https://www.dotbio.com/

Source: Protect Animal Health